Atopic Dermatitis (NEURADAD Study)

Study Description

Brief Summary

Primary Objective: Part A

  • To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners’ Continuous Performance Test 3rd Edition (CPT-3) d’ T-score
  • To determine the entry criterion (CPT-3 d’ score) for Part B

Primary Objective: Part B

  • To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab

Secondary Objectives

  • To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients
  • To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).

Condition or Disease

Moderate-to-severe Atopic Dermatitis

Study Design

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 82 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis
Actual Study Start Date: January 27, 2022
Estimated Primary Completion Date: July 15, 2024
Estimated Study Completion Date: August 12, 2024

Eligibility Criteria

Ages Eligible for Study: 12 Years to 17 Years   (Child)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Inclusion Criteria

  • Adolescent (12 – 17 years of age) Part A: at time of visit Part B: at time of screening visit
  • Diagnosis of atopic dermatitis (AD) according to American Academy of Dermatology consensus criteria; chronic AD Part A: first diagnosed at least 1 year prior to visit Part B: first diagnosed at least 1 year prior to the screening visit
  • EASI score ‚Č• 12 Part A: at time of visit Part B: at screening and baseline visits
  • IGA score ‚Č• 3 Part A: at time of visit Part B: at time of screening and baseline visits
  • Peak Pruritus NRS score ‚Č• 4 Part A: at time of visit Part B: at time of screening and baseline visits as defined in the protocol
  • The CPT-3 d’ score for entry into Part B will be determined based on the distribution of the CPT-3 d’ score from Part A
  • BSA of AD involvement ‚Č• 10% Part A: at time visit Part B: at screening and baseline visits
  • Part B Only: Documented recent history (within 6 months of the screening visit) of inadequate response (in the opinion of the investigator) to topical AD medication(s) or for whom topical AD medications are medically inadvisable as defined in the protocol
  • Part B Only: Patient’s stable use of a prescription topical medication regimen for AD lesions for at least 2 weeks prior to baseline as defined in the protocol

Exclusion Criteria

  • Prior use of dupilumab Part A: within 6 months of visit Part B: within 6 months of screening
  • Skin diseases that could confound AD assessment as defined in the protocol
  • Treatment with methylphenidate, dexmethylphenidate, serdexmethylphenidate, amphetamine, dextroamphetamine, lisdexamfetamine, guanfacine, atomoxetine, clonidine, or viloxazine within 8 weeks or within 5 half-lives, whichever is longer, at visit
  • History of clinician-diagnosed attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, epilepsy, major depressive disorder, mania or bipolar disorder, or any Diagnostic and Statistical Manual-V (DSM-V) psychotic disorder, such as schizophrenia
  • Evidence of substance abuse, including alcohol and nicotine, in the past 2 years
  • Systemic antihistamine or nicotine use Part A: within the week prior to the visit Part B: during the week prior to screening
  • Part B Only: Active helminthic infections; suspected or high risk of helminthic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before baseline
  • Part B Only: At baseline, presence of any conditions listed as criteria for study drug discontinuation
  • Part B Only: Treatment with high potency or super-potent TCS within 14 days prior to baseline

NOTE: Other protocol defined inclusion/exclusion criteria apply

ADDITIONAL DETAILS